Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,833 INR | +1.50% | +3.80% | +12.80% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- With an expected P/E ratio at 47.06 and 37.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.80% | 3.37B | - | ||
+35.01% | 709B | C+ | ||
+30.50% | 595B | B | ||
-2.60% | 367B | C+ | ||
+20.83% | 334B | B- | ||
+5.69% | 289B | C+ | ||
+14.47% | 239B | B+ | ||
+9.41% | 211B | B- | ||
-3.68% | 203B | A+ | ||
+10.77% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JBCHEPHARM Stock
- JBCHEPHARM Stock
- Ratings J. B. Chemicals & Pharmaceuticals Limited